KOSDAQ

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Toxicity, Therapeutic index, KOSDAQ, Partnership, MMAE, Breast, Cancer, Spacecraft, CDX, AACR, PDX, Neoplasm, Pharmacokinetics, LCB, EC50, ADC

The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.

Key Points: 
  • The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
  • The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers.
  • LNCB74 was shown to specifically bind to B7-H4 expressing tumor cells and was rapidly internalized in a target-dependent manner.
  • “These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications.

SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Manufacturing, FDA, Health, Pharmaceutical, Oncology, Research, Genetics, Engineering, Science, Clinical Trials, OS, Regeneron Pharmaceuticals, KOSDAQ, Patient, Renal cell carcinoma, Trial of the century, ICI, RCC, CSR, Safety, ICIS

SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).

Key Points: 
  • SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
  • In 2017, SillaJen began a collaboration agreement with Regeneron for the clinical study of Pexa-Vec in combination with cemiplimab in patients with RCC.
  • The study was conducted in four study arms (A to D) to assess the safety and efficacy of the Pexa-Vec in combination with cemiplimab.
  • Given the typically lower response rates in patients with more prior extensive treatments, the results are considered highly encouraging.

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medication, KOSDAQ, Partnership, CNS, Epitope, CMC, Quality of life, ABL, Antibody, HKEX, Therapy, ADC

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
  • Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
  • Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases.
  • Together, we aim to expedite the development of innovative bsADC therapies.”
    Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs.

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Medication, KOSDAQ, Partnership, CNS, Epitope, Research, CMC, Quality of life, ABL, Antibody, HKEX, Therapy, ADC

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
  • Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
  • Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases.
  • Together, we aim to expedite the development of innovative bsADC therapies.”
    Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs.

NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer

Retrieved on: 
Tuesday, April 2, 2024
Mallinckrodt, Inflammation, Pharmacology, McGill University, Organization, Acute radiation syndrome, ARS, KOSDAQ, Research, EDT, Senior, Doctor of Philosophy, IL-7, Human Genome Sciences, Drug development, Division, NIT, Vertex Pharmaceuticals

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).

Key Points: 
  • ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT).
  • Se Hwan Yang, Ph.D., as Chief Executive Officer of NeoImmuneTech, Inc.
  • In his new role, Dr. Oh will lead NeoImmuneTech from its Rockville headquarters and overview all the operations in Korea.
  • Se Hwan Yang initiated, aligning the company on our business priorities, and stepping up this new phase of NeoImmuneTech."

Fingerlabs Exclusively Premieres 'Begins Youth', a Derivative Drama Based on BTS' 'Hwa Yang Yeon Hwa', through Xclusive

Retrieved on: 
Tuesday, April 2, 2024
Ethereum, Bybit, Attention, Digital, KOSDAQ, Light, OTT, Chorokbaem Media, Mantle, BTS, Sale, JTBC, HYBE, Web 3.0, IP, Security token, FSN, Multimedia, IPS, OGN, Mobile phone

'Begins Youth', co-produced by Chorokbaem Media and HYBE, is a derivative drama that reconfigures the 'Hwa Yang Yeon Hwa' story previously explored through BTS' albums, music videos, and other official content since 2015.

Key Points: 
  • 'Begins Youth', co-produced by Chorokbaem Media and HYBE, is a derivative drama that reconfigures the 'Hwa Yang Yeon Hwa' story previously explored through BTS' albums, music videos, and other official content since 2015.
  • This derivative drama, inspired by BTS 'Hwa Yang Yeon Hwa', combines fiction with the group's established story.
  • The premiere trailer for 'Begins Youth' was unveiled in Paris, France, in May of the previous year, attracting considerable attention.
  • This innovative approach is exclusively facilitated through Xclusive, developed on the Mantle Network — an Ethereum Layer 2 network associated with the global cryptocurrency exchange 'Bybit'.

The Global Parkinson's Genetics Program and Psomagen Inc. Make Agreement with Goal to Transform Parkinson's Disease Genetics Research and Patient Outcomes

Retrieved on: 
Monday, March 18, 2024
WGS, Organization, ASAP, Parkinson's disease, Coalition, Disease, KOSDAQ, PD, Genetics, Patient, Research, MJFF, Science, CAP, Doctor of Philosophy, Laboratory, CLIA, Whole genome sequencing, Bangladesh Technical Education Board, ISO

The program will run over the next 2.5 - 3 years using Illumina sequencing instruments and reagents.

Key Points: 
  • The program will run over the next 2.5 - 3 years using Illumina sequencing instruments and reagents.
  • GP2 is a program supported by the Aligning Science Across Parkinson's (ASAP) initiative managed by the Coalition for Aligning Science and implemented by The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) and is focused on improving our understanding of the genetic architecture of Parkinson's disease and making this knowledge globally relevant.
  • GP2 specifically has the goal of including groups traditionally underrepresented in genetics research, to diversify its understanding of PD by focusing on inclusion in the research pipeline.

Seoul Robotics Explores Partnership in Industrial Autonomous Driving R&D with UAE's Advanced Technology Research Council (ATRC)

Retrieved on: 
Monday, March 11, 2024
KRW, Organization, Environment, Original equipment manufacturer, KOSDAQ, Agriculture, Partnership, Zawar Farid, Robotics, Food, IPO, POC, Council, ATRC, Safety, Traffic management, Advanced Technology Research Council

SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- Seoul Robotics, a leading industrial autonomous driving company, recently engaged in discussions with Abu Dhabi's Advanced Technology Research Council (ATRC) in the United Arab Emirates (UAE), to explore partnership prospects for joint research and development (R&D) in the field.

Key Points: 
  • SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- Seoul Robotics, a leading industrial autonomous driving company, recently engaged in discussions with Abu Dhabi's Advanced Technology Research Council (ATRC) in the United Arab Emirates (UAE), to explore partnership prospects for joint research and development (R&D) in the field.
  • The discussions focused on introducing Seoul Robotics and sharing insights into the current state and future outlook of the industrial autonomous driving market, with emphasis on potential collaboration opportunities across R&D.
  • Lee Han-bin, CEO of Seoul Robotics, expressed the significance of ATRC's visit and the discussions on partnership as a testament to Seoul Robotics' competitive edge in the industrial autonomous driving sector.
  • Founded in 2017, Seoul Robotics has established itself as a key player in the industrial autonomous driving software market, serving major global automotive OEMs.

S.BIOMEDICS completes brain transplant of hESC-derived dopaminergic progenitors (TED-A9) for Phase 1/2a study in patients with Parkinson’s disease

Retrieved on: 
Thursday, February 29, 2024
Stem Cells, Data Management, Biotechnology, Technology, Health, Neurology, Research, Hospitals, Surgery, Science, Clinical Trials, Severance Hospital, Dyskinesia, KOSDAQ, Safety, Neuron, Yonsei University, DLT, Freezing, Cell, Parkinson's disease, Transplant, Putamen, Patient, Clinical trial, Gait, Brain, Pharmaceutical industry

S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.

Key Points: 
  • S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson's disease.
  • The primary objective of the Phase 1/2a trial is to assess the safety and exploratory efficacy of TED-A9 transplantation for two years post-transplant.
  • “We have developed a fundamental therapeutic mechanism that directly replaces dopaminergic neurons lost in patients with Parkinson's disease.
  • TED-A9 could represent a fundamental treatment that surpasses current therapies, which only temporarily alleviate the symptoms of Parkinson’s disease,” he added.

Genians Achieves Milestone Revenue Growth: NAC Innovation and Global Expansion

Retrieved on: 
Monday, February 26, 2024
Data Management, Security, IOT (Internet of Things), Technology, Software, Networks, ICT, Ministry of Science, KOSDAQ, Ministry, Education, Health, Growth, NAC, Government, EDR, Zero trust security model, Private sector, ZTNA, Organization, Telecommunications, Network Access Control, DPI

This remarkable success can be attributed to the sustained growth of Genians' Network Access Control (NAC) solutions.

Key Points: 
  • This remarkable success can be attributed to the sustained growth of Genians' Network Access Control (NAC) solutions.
  • Looking ahead, Genians is poised to bolster its global business endeavors this year, with a key focus on sustaining revenue growth momentum.
  • Now, we're amplifying our global presence to seize new opportunities and make 2024 a landmark year for Genians."
  • Genians is working to build a better security culture in the connected world by teaming up with global communities and industry leaders around the world.